Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ESC PCI gui<strong>del</strong>ines 2004<br />
2004 Recommendations for anti-thrombotic<br />
thrombotic<br />
medications for PCI in UA/NSTEMI<br />
Procedure<br />
ASA<br />
Clopidogrel<br />
Indication<br />
All procedures<br />
Immediately (if clinically justifiable) and prolonged for 9-12<br />
months<br />
Recommendation<br />
I C<br />
I B<br />
Studies for<br />
Level A or B<br />
-<br />
CURE<br />
GP <strong>IIb</strong>/<strong>IIIa</strong><br />
inhib<strong>it</strong>or<br />
Abciximab<br />
Immediately before PCI in high-risk ACS<br />
I A<br />
CAPTURE, EPIC<br />
GP <strong>IIb</strong>/<strong>IIIa</strong><br />
inhib<strong>it</strong>or<br />
Eptifibatide<br />
Immediately before PCI in high-risk ACS<br />
I C<br />
-<br />
GP <strong>IIb</strong>/<strong>IIIa</strong><br />
inhib<strong>it</strong>or<br />
Tirofiban,<br />
Eptifibatide<br />
“Upstream” in high-risk ACS: pretreatment (48-72 hrs) before<br />
angiography and PCI<br />
I C<br />
-<br />
Enoxaparin<br />
Bivalirudin<br />
Replacement for UFH in high-risk NSTE-ACS, if invasive<br />
strategy is not applicable<br />
Replacement for UFH (± GP <strong>IIb</strong>/<strong>IIIa</strong> inhib<strong>it</strong>ors) to reduce<br />
bleeding complications<br />
I C -<br />
II a C -
Change language